Osteonecrosis of the jaw related to bevacizumab.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Oncology

• Publication date

  2008-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2007.15.5424PMID 18711196
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer

  2007cited by this paper
• Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

  2007cited by this paper
• Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.

  2006cited by this paper
• Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.

  2006cited by this paper
• Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

  2006cited by this paper
• Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

  2006cited by this paper
• Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.

  2006cited by this paper
• Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

  2006cited by this paper
• Bevacizumab-induced nasal septum perforation.

  2006cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Clinical translation of angiogenesis inhibitors

  2002cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper

• Which monoclonal antibodies cause osteonecrosis of the jaws? An overview of the current literature excluding denosumab.

  2026cites this paper
• Navigating Stomatologic Complications Secondary to Antineoplastic Agents—A Comprehensive Review

  2025cites this paper
• Antibiotic Prophylaxis and Postoperative Therapy in Tooth Extractions for Patients at Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Scoping Review

  2025cites this paper
• A case of medication-related osteonecrosis of the jaw was suspected to be associated with romosozumab.

  2025cites this paper
• Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption

  2025influential citation
• A literature review and update on medications related to osteonecrosis of the jaw independent of bisphosphonates and denosumab

  2025cites this paper
• Exploring the Impact of Novel Anti-Cancer Therapies on Jaw Osteonecrosis and Other Bones: A Comprehensive Review

  2024cites this paper
• Treatment of Bisphosphonate-related Osteonecrosis of Jaw (BRONJ) in Rabbit Model: A Proof-of-concept Animal Study Comparing Angiogenesis Factor Versus Autologous Bone Marrow-derived Osteoblasts (ABMDO)

  2024cites this paper
• A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials

  2024cites this paper
• Ibrutinib-associated osteonecrosis of the jaw

  2024cites this paper
• Volumetric analysis of spontaneous bone formation after segmental mandibulectomy in patients with MRONJ.

  2024cites this paper
• A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab

  2023cites this paper
• The Role of Imaging in Mandibular Reconstruction with Microvascular Surgery.

  2023cites this paper
• Case reporting in oral and maxillofacial pathology: Requisite among rare diseases

  2023cites this paper
• Osteonecrosis of the Jaw

  2023cites this paper
• Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Survey among Urologists in Switzerland, Germany, and Austria

  2023cites this paper
• The Role of Dental Practitioners in the Management of Oncology Patients: The Head and Neck Radiation Oncology Patient and the Medical Oncology Patient

  2023cites this paper
• Spontaneous Osteogenic Potential of Periosteum after Segmental Mandibulectomy in Patients with Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Study of 14 Cases

  2023cites this paper
• Contribution of Antiangiogenic Agents to the Risk of Medication-related Osteonecrosis of the Jaw in Combination with Antiresorptive Agents: Preliminary Results in a Comparative Prospective Report of 59 Oncologic Cases

  2022cites this paper
• Medication-Related Osteonecrosis of the Jaw Associated with Pazopanib Monotherapy

  2022cites this paper
• Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro

  2022cites this paper
• Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

  2022cites this paper
• In reply

  2022cites this paper
• Medication-related osteonecrosis of the jaw in cancer patients: Case series and review of the current literature

  2022cites this paper
• Dental Awareness and Barriers in Reducing the Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) Among Non-head and Neck Cancer Patients

  2022cites this paper
• Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review

  2021cites this paper
• Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review

  2021cites this paper
• Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

  2021cites this paper
• Preventing or Controlling Periodontitis Reduces the Occurrence of Osteonecrosis of the Jaw (ONJ) in Rice Rats (Oryzomys palustris).

  2021cites this paper
• Ramucirumab-related osteonecrosis of the jaw.

  2021cites this paper
• Oral mucosal pseudotumor - Novelty complication in patient undergoing bevacizumab therapy.

  2021cites this paper
• Osteonecrosis of the jaw associated with receiving sunitinib monotherapy: A rare case

  2021cites this paper
• Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics.

  2021cites this paper
• Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series.

  2021cites this paper
• Zoledronic Acid Induces Early Changes of VEGF Levels in Women With Postmenopausal Osteoporosis

  2021cites this paper
• New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): review of the literature and single-center experience.

  2021cites this paper
• Adverse events associated with bone-directed therapies in patients with cancer.

  2021cites this paper
• Preclinical Models of Medication-related Osteonecrosis of the Jaw (MRONJ).

  2021cites this paper
• Osteomyelitis, Osteoradionecrosis, and Medication-Related Osteonecrosis of Jaws

  2021cites this paper
• Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D

  2021cites this paper
• Complementarity of Photo-Biomodulation, Surgical Treatment, and Antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ)

  2021cites this paper
• Unexpected massive bleeding caused by extensive maxillary osteonecrosis in a breast cancer patient: a case report

  2021cites this paper
• Application of Photodynamic Therapy in the Treatment of Osteonecrosis of the Jaw

  2020cites this paper
• New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

  2020cites this paper
• Is Bevacizumab a Direct Cause of Osteonecrosis of the Jaw like Bisphosphonate

  2020cites this paper
• Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) – A primary prevention strategy

  2020cites this paper
• Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression

  2020cites this paper
• Medication related jaw osteonecrosis (MRONJ) late onset 3 years after IPILIMUMAB endovenous administration: a possible role of target therapy

  2020cites this paper
• Nationwide Multicentric Retrospective and Prospective Epidemiologic Survey of Bisphosphonate-related Osteonecrosis of the Jaws

  2020cites this paper
• Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals

  2020cites this paper
• Medication-related osteonecrosis of the jaw (MRONJ): An update on the Memorial Sloan Kettering Cancer Center (MSKCC) experience and the role of Pre-medication Dental Evaluation in the prevention of MRONJ

  2020cites this paper
• Actualización de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisión de literatura

  2020cites this paper
• Deciphering novel chemotherapy and its impact on dentistry

  2020cites this paper
• Adverse Drug Events in the Oral Cavity.

  2020cites this paper
• Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?

  2020cites this paper
• Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.

  2019cites this paper
• Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

  2019cites this paper
• Osteonecrosis in pediatric cancer survivors: Epidemiology, risk factors, and treatment.

  2019cites this paper
• Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports

  2019cites this paper
• Pharmacogenomics of osteonecrosis of the jaw.

  2019cites this paper
• Pharmacogenomics in medication-related osteonecrosis of the jaw: a systematic literature review.

  2019cites this paper
• Osteonecrosis of the Jaw in a Patient With Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab

  2019cites this paper
• A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants

  2019cites this paper
• Risk profile for antiangiogenic agent-related osteonecrosis of the jaws

  2019influential citation
• Effect of antiangiogenic targeted chemotherapy on the osseointegration of titanium implants in rabbits.

  2019cites this paper
• Medication-Related Osteonecrosis of the Jaws.

  2019cites this paper
• Osteonecrosis of the Jaw in a Patient With Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab

  2019cites this paper
• Risk factors for medication-related osteonecrosis of the jaws: a case-control study in Queensland, Australia

  2019cites this paper
• Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.

  2019cites this paper
• Osteonecrosis of the Jaw in a Patient Treated with Denosumab and

  2018cites this paper
• Radiographic predictors of bone exposure in stage 0 MRONJ patients

  2018cites this paper
• Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature

  2018cites this paper
• Osteonecrosis of the Jaw in a Patient With Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab

  2018cites this paper
• Oral adverse events associated with targeted cancer therapies.

  2018cites this paper
• Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws.

  2018cites this paper
• Osteonecrosis of the Jaw in a Patient With Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab

  2018cites this paper
• Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review.

  2018cites this paper
• Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.

  2018cites this paper
• Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review

  2018cites this paper
• Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.

  2018cites this paper
• This is a repository copy of Severe Compromise of Preosteoblasts in a Surgical Mouse Model of Bisphosphonate-Associated Osteonecrosis of the Jaw.

  2018cites this paper
• Risk factors for medication-related osteonecrosis of the jaws: A systematic review.

  2018cites this paper
• [Progress on medication-related osteonecrosis of the jaw].

  2018cites this paper
• Selective Percutaneous Controlled Radiofrequency Thermocoagulation of the Gasserian Ganglion To Control Facial Pain Due to Medication-Related Osteonecrosis of the Jaw

  2017cites this paper
• Denosumab-related osteonecrosis of the jaw: A literature review

  2017cites this paper
• Axitinib-related osteonecrosis of the jaw.

  2017cites this paper
• Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.

  2017influential citation
• Osteonecrosis of the Jaw in a Patient Treated with Denosumab and Temsirolimus

  2017cites this paper
• Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report.

  2017cites this paper
• Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?

  2017cites this paper
• Antiresorptive treatment‐associated ONJ

  2017cites this paper
• Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid

  2017cites this paper
• A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians

  2017cites this paper
• Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case Report

  2017cites this paper
• Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti‐angiogenic therapy with bevacizumab

  2016cites this paper
• Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases

  2016cites this paper
• Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

  2016cites this paper
• Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.

  2016cites this paper
• Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw.

  2016cites this paper
• Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

  2016cites this paper